Pituitary carcinoma.
Ciric IS.
World Neurosurg. 2013 Nov;80(5):e147-9. doi: 10.1016/j.wneu.2011.06.002. Epub 2011 Nov 7.
Immune-checkpoint inhibitors in pituitary malignancies.
Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA.
Anticancer Drugs. 2022 Jan 1;33(1):e28-e35. doi: 10.1097/CAD.0000000000001157.
Pathogenesis of pituitary tumors.
Melmed S.
Nat Rev Endocrinol. 2011 May;7(5):257-66. doi: 10.1038/nrendo.2011.40. Epub 2011 Mar 22.
Pediatric pituitary adenomas.
Kunwar S, Wilson CB.
J Clin Endocrinol Metab. 1999 Dec;84(12):4385-9. doi: 10.1210/jcem.84.12.6240.
Malignant pituitary tumours.
Kaltsas GA, Grossman AB.
Pituitary. 1998 Apr;1(1):69-81. doi: 10.1023/a:1009975009924.
Ectopic pro-opiomelanocortin syndrome.
Beuschlein F, Hammer GD.
Endocrinol Metab Clin North Am. 2002 Mar;31(1):191-234. doi: 10.1016/s0889-8529(01)00025-1.
Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases.
Shastri BR, Nanda A, Fowler M, Levine SN.
World Neurosurg. 2013 Feb;79(2):404.e11-6. doi: 10.1016/j.wneu.2011.04.018. Epub 2011 Nov 10.
Pituitary tumors.
Ontjes DA, Ney RL.
CA Cancer J Clin. 1976 Nov-Dec;26(6):330-50. doi: 10.3322/canjclin.26.6.330.
Pituitary carcinoma: a review of the literature.
Ragel BT, Couldwell WT.
Neurosurg Focus. 2004 Apr 15;16(4):E7. doi: 10.3171/foc.2004.16.4.8.
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators †.
Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.
